A Randomized Double-Masked Study of 50 mg of Acarbose versus 0.2 mg Voglibose in Overweight Type 2 Diabetes Patients Age Between 30 and 50 Years Having Isolated Postprandial Glycemia.

Objective: To compare the efficacy of 50 mg acarbose versus 0.2 mg of voglibose in treating postprandial hyperglycemia. Material and methods: A randomized double-masked study was conducted at the Hassan Obesity and Diabetes Wellness Centre, Hassan, Karnataka, in coordination with Rajiv Gandhi University of Health Sciences, Karnataka. Sixty cases of isolated high postprandial blood sugar (PPBS > 200 mg/dL FBS < 126 mg/dL), including both males and females between age group 30 and 50 years, were included in the study group. Observation and results: Out of 30 patients in the group treated with acarbose 50 mg, the mean reduction of glycosylated hemoglobin (HbA1C) to their baseline values was 0.8% and mean reduction in the postprandial values was 64 mg/dL. Out of 30 patients in the group treated with voglibose 0.2 mg, the mean reduction in the HbA1C was 0.6% and mean reduction in the postprandial values was 57 mg/dL. Conclusions: Reduction of postprandial blood glucose and HbA1C were more in the group treated with acarbose with the difference of 0.2% in HbA1C and 7-8 mg/dL (mean) in postprandial plasma glucose. The side effects were more in the group treated with acarbose when compared with group treated with voglibose.